Mesoblast (NASDAQ:MESO) Shares Gap Up to $7.24

Mesoblast Limited (NASDAQ:MESOGet Free Report)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $7.24, but opened at $7.39. Mesoblast shares last traded at $7.51, with a volume of 5,424 shares.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research report on Tuesday, June 4th. StockNews.com cut Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $13.67.

View Our Latest Research Report on Mesoblast

Mesoblast Stock Performance

The firm has a 50-day simple moving average of $6.93 and a two-hundred day simple moving average of $4.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Mesoblast stock. Chase Investment Counsel Corp bought a new stake in shares of Mesoblast Limited (NASDAQ:MESOFree Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 59,600 shares of the company’s stock, valued at approximately $298,000. Chase Investment Counsel Corp owned approximately 0.05% of Mesoblast at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.43% of the company’s stock.

About Mesoblast

(Get Free Report)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Featured Stories

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.